Buscar
Mostrando ítems 1-10 de 11
Hepatitis delta in patients with resolved hepatitis B virus infection
(European Journal of Gastroenterology & Hepatology, 2018-09)
Background The hepatitis delta virus (HDV) causes the most aggressive form of chronic viral hepatitis. As HDV replication requires hepatitis B virus (HBV), HDV screening is limited to HBsAg+ carriers. To date, individuals ...
Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain
(European Journal of Gastroenterology & Hepatology, 2018-09)
Background Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following acute dual ...
Occult hepatitis B and HIV infection
(European Journal of Gastroenterology & Hepatology, 2019-11)
Introduction Occult hepatitis B virus (HBV) infection, so-called occult B infection (OBI), is defined by the recognition of HBV-DNA in the absence of serum hepatitis B surface antigen (HBsAg). The HBV-DNA genome in OBI is ...
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain
(Hepatology International, 2022)
Background: Chronic viral hepatitis B, C, and D are the main causes of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented more than 2 decades ago in most EU countries. Furthermore, ...
Viral hepatitis in persons living with HIV in the post-COVID era
(AIDS reviews, 2023)
Coinfection with hepatitis viruses A to E is frequent in persons living with HIV (PLWH) and causes significant morbidity and mortality. Oro-fecal transmissible hepatitis A and E mostly produce acute self-limited episodes ...
The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America
(Journal of Clinical Virology, 2022)
Background: Hepatitis B virus (HBV) comprises 9 genotypes and multiple subgenotypes that depict differences in geographic distribution, clinical outcome and response to antiviral therapy. However, the molecular epidemiology ...
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain
(Alimentary Pharmacology and Therapeutics, 2023)
Background: Chronic hepatitis B virus (HBV) infection is a major cause of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented in Spain two decades ago, and potent oral antivirals ...
Envisioning hepatitis delta cure without functional hepatitis B cure
(AIDS reviews, 2022)
[abstract not available]
Less hepatic decompensation events but rising liver cancer in hepatitis B patients on long-term nucleos(t)ide therapy
(AIDS Reviews, 2022)
[Abstract not available]
Susceptibility to hepatitis B virus infection in adults living in Spain
(Liver International, 2023)
BackgroundA protective hepatitis B virus (HBV) vaccine has been available for four decades. Universal HBV vaccination of infants is recommended by the WHO since the 1990s. Furthermore, HBV immunization is advised for all ...